Xponance LLC Purchases 15,650 Shares of Abbott Laboratories $ABT

Xponance LLC increased its position in shares of Abbott Laboratories (NYSE:ABT) by 6.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 274,240 shares of the healthcare product maker’s stock after acquiring an additional 15,650 shares during the quarter. Xponance LLC’s holdings in Abbott Laboratories were worth $34,360,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the 4th quarter worth approximately $25,000. Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories during the 4th quarter worth approximately $27,000. Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories during the 3rd quarter worth approximately $33,000. Prudent Man Investment Management Inc. bought a new position in Abbott Laboratories during the 4th quarter worth approximately $33,000. Finally, Leonteq Securities AG bought a new position in Abbott Laboratories during the 4th quarter worth approximately $35,000. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $89.65 on Friday. The stock has a market capitalization of $156.14 billion, a P/E ratio of 25.11, a P/E/G ratio of 1.49 and a beta of 0.63. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a 50 day moving average of $91.75 and a 200-day moving average of $108.12. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott helped lead the first close of Star51 Capital’s inaugural medtech venture fund, highlighting its commitment to healthcare innovation and potential future deal flow in medtech. Star51 Capital Announces First Close of Medtech Venture Fund
• Positive Sentiment: Abbott received more support for its diabetes and cancer diagnostics growth story, including CE Mark approval for Libre Duo and updated colorectal cancer screening guidance favoring its tests, which could support long-term revenue growth. Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness
• Positive Sentiment: Abbott’s expanded agreement with MiniMed to commercialize dual glucose-ketone sensors adds another growth avenue in diabetes care and strengthens its connected-device strategy. This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In
• Neutral Sentiment: ABBT was noted as a trending stock on Zacks, suggesting elevated investor attention but not a clear fundamental catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analysts on balance were slightly more cautious, with Erste Group trimming its FY2027 EPS estimate only marginally to $6.04 from $6.05, a small change that does not signal a major shift in outlook. Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT)
• Negative Sentiment: Some investors also pointed to weakness in the stock itself, with recent trading showing ABT underperforming the broader market, suggesting sentiment remains pressured despite the positive product news. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Wall Street Analyst Weigh In

ABT has been the topic of several recent analyst reports. Barclays reduced their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. UBS Group dropped their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Argus dropped their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Evercore dropped their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $119.09.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.